Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 12/20 | 0.55 |
| ▸ | F13A1 | P00488 | 9/20 | 0.55 |
| ▸ | TGM1 | P22735 | 6/20 | 0.55 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | STS | P08842 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13239816 | 0.95 | TGM2 (0.59) | TGM2F13A1TGM1TGM3STS | |
| SCHEMBL28919020 | 0.82 | STS (0.63) | TGM2F13A1TGM1TGM3KMT2A | |
| SCHEMBL5262401 | 0.81 | TGM2 (0.51) | TGM2F13A1TGM1TGM3 | |
| SCHEMBL1180627 | 0.81 | TGM2 (0.60) | TGM2F13A1TGM1TGM3KMT2A | |
| SCHEMBL29060789 | 0.80 | MAPT (0.73) | TGM2F13A1TGM1TGM3KMT2A | |
| SCHEMBL5235579 | 0.80 | MEN1 (0.59) | KMT2AMEN1STSMAPTLMNA | |
| SCHEMBL2252120 | 0.79 | TGM2 (0.63) | TGM2F13A1TGM1KMT2ALMNA | |
| SCHEMBL20100253 | 0.79 | TGM2 (0.49) | TGM2F13A1TGM1TGM3LMNA | |
| SCHEMBL4266289 | 0.79 | CNR1 (0.59) | TGM2F13A1TGM1TGM3KMT2A | |
| SCHEMBL1955697 | 0.79 | ALDH1A1 (0.62) | TGM2F13A1TGM1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586577-B2 | Diazepane acetamide derivatives as selective 11B-HSD1 inhibitors | MERCK PATENT GMBH (DE) | 2013-11-19 | — | — | US | disclosed |
| US-20120283247-A1 | DIAZEPANE ACETAMIDE DERIVATIVES AS SELECTIVE 11B-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2012-11-08 | — | — | US | disclosed |
| EP-2078001-B8 | DIAZEPANE-ACETAMIDE DERIVATIVES AS SELECTIVE 11 -HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2010-12-15 | — | — | EP | disclosed |
| EP-2078001-B1 | DIAZEPANE-ACETAMIDE DERIVATIVES AS SELECTIVE 11 -HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2010-05-12 | — | — | EP | disclosed |
| EP-2078001-A1 | DIAZEPANE-ACETAMIDE DERIVATIVES AS SELECTIVE 11 -HSD1 INHIBITORS | Merk Patent Gmbh (DE) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008052638-A1 | DIAZEPANE-ACETAMIDE DERIVATIVES AS SELECTIVE 11β-HSD1 INHIBITORS | MERK PATENT GMBH (DE) | 2008-05-08 | — | — | WO | disclosed |
| EP-1918285-A1 | Diazepane-acetamide derivatives as selective 11beta-HSD1 inhibitors | Merck Sante (FR) | 2008-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283247-A1 | DIAZEPANE ACETAMIDE DERIVATIVES AS SELECTIVE 11B-HSD1 INHIBITORS | HSD11B1, HSD11B2, HSD17B1 | TGM2 2212/4885F13A1 2570/4885TGM1 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.